NILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES

Yavuz A. S., Elcioglu O. C., Akpinar T. S., Cosan F., Ucur A., Bayrak A., ...More

NOBEL MEDICUS, vol.6, no.2, pp.57-62, 2010 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 6 Issue: 2
  • Publication Date: 2010
  • Journal Name: NOBEL MEDICUS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.57-62
  • Keywords: chronic myeloid leukemia, nilotinib, tyrosine kinase inhibitors, cytogenetics, clonal aberrations, CHRONIC MYELOGENOUS LEUKEMIA, PHILADELPHIA-NEGATIVE CELLS, TYROSINE KINASE INHIBITOR, DASATINIB THERAPY, FORMERLY AMN107, HEMATOPOIESIS, ABNORMALITIES, EVOLUTION
  • Istanbul University Affiliated: Yes

Abstract

Objective: Clonal cytogenetic aberrations other than Philadelphia chromosome can develop during the course of chronic myeloid leukemia naturally or under the pressure of treatment strategies like interferon, imatinib and dasatinib. Some of them are associated with resistance to treatment and progression to advanced phases of chronic myeloid leukemia. Nilotinib is a second generation thyrosine kinase inhibitor, but its efficacy in chronic myeloid leukemia patients with additional chromosomal changes has not been delineated yet. In this study we evaluated the efficacy of nilotinib in imatinib-resistant or -intolerant t(9;22) positive chronic myeloid leukemia patients with and without additional chromosomal changes